185110-06-9

Basic information

• Product Name: 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE
• Synonyms: 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE;Piperazine, 2-(3,4-dichlorophenyl)-;2-(3,4-Dichlorophenyl)piperazine 2HCl
• CAS NO: 185110-06-9
• Molecular Formula: C₁₀H₁₂Cl₂N₂
• Molecular Weight: 231.12
• Product Categories: pharmacetical
• Mol File: 185110-06-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 348.1°Cat760mmHg
• Flash Point: 164.3°C
• Appearance: /
• Density: 1.238g/cm³
• Vapor Pressure: 5.14E-05mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE(185110-06-9)
• EPA Substance Registry System: 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE(185110-06-9)

Safety Data

• Hazardous Substances Data: 185110-06-9(Hazardous Substances Data)

Usage

General Description

2-(3,4-Dichloro-phenyl)-piperazine is a chemical compound that belongs to the class of piperazine derivatives. It is a phenylpiperazine derivative with two chlorine atoms substituted on the 3 and 4 positions of the phenyl ring. 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE is commonly used as a precursor in the synthesis of various pharmaceutical drugs, including antipsychotic and antihistaminic medications. It has also been studied for its potential therapeutic effects in neurological and psychiatric disorders. Additionally, this chemical has been investigated for its potential use as an intermediate in organic synthesis and as a ligand in chemical catalysis. Due to its biological and pharmacological activities, 2-(3,4-Dichloro-phenyl)-piperazine is of interest in the fields of medicinal chemistry and drug discovery.

InChI:InChI=1/C10H12Cl2N2/c11-8-2-1-7(5-9(8)12)10-6-13-3-4-14-10/h1-2,5,10,13-14H,3-4,6H2

Upstream product

• 2632-10-2 2-bromo-1-(3,4-dichlorophenyl)ethanone 
• 107-15-3 ethylenediamine 
• 38923-36-3 2-(3,4-dichlorophenyl)-2-oxoacetaldehyde 
• 7757-82-6 sodium sulfate 
• 4530-20-5 BOC-glycine 
• 185110-30-9 2-(R,S)-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)piperazine 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 334477-10-0 3-(3,4-dichloro-phenyl)-piperazin-2-one 
• 163339-71-7 α-bromo-3,4-dichlorophenylacetic acid methyl ester 
• 6725-44-6 methyl 2-(3,4-dichlorophenyl)acetate 

Downstream Products

• 185110-30-9 2-(R,S)-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)piperazine 
• 185108-47-8 (+/-)-2-(3,4-dichlorophenyl)-4-[(4-fluoro-1-naphthalenyl)carbonyl]-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]acetyl]piperazine 
• 185108-18-3 2-(1-Benzyl-piperidin-4-ylamino)-1-[(R)-2-(3,4-dichloro-phenyl)-4-(3,5-dimethyl-benzoyl)-piperazin-1-yl]-ethanone 
• 185108-18-3 2-(1-Benzyl-piperidin-4-ylamino)-1-[(S)-2-(3,4-dichloro-phenyl)-4-(3,5-dimethyl-benzoyl)-piperazin-1-yl]-ethanone 
• 185108-18-3 (+/-)-4-[3,5-dimethylbenzoyl]-2-(3,4-dichlorophenyl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]acetyl]piperazine 

Relevant articles and documents

Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors

We herein describe the results of further evolution of glycogen synthase kinase (GSK)-3β inhibitors from our promising compounds containing a 2-phenylmorpholine moiety. Transformation of the morpholine moiety into a piperazine moiety resulted in potent GSK-3β inhibitors. SAR studies focused on the phenyl moiety revealed that a 4-fluoro-2-methoxy group afforded potent inhibitory activity toward GSK-3β. Based on docking studies, new hydrogen bonding between the nitrogen atom of the piperazine moiety and the oxygen atom of the main chain of Gln185 has been indicated, which may contribute to increased activity compared with that of the corresponding phenylmorpholine analogues. Effect of the stereochemistry of the phenylpiperazine moiety is also discussed.

PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS

-

PIPERAZINO DERIVATIVES AS NEUROKINN ANTAGONISTS

-